Roseotoxin B Improves Allergic Contact Dermatitis Through a Unique Anti-Inflammatory Mechanism Involving Excessive Activation of Autophagy in Activated T Lymphocytes

Xingqi Wang,Chunhui Hu,Xingxin Wu,Shiyu Wang,Aihua Zhang,Wei Chen,Yan Shen,Renxiang Tan,Xuefeng Wu,Yang Sun,Qiang Xu
DOI: https://doi.org/10.1016/j.jid.2016.04.017
IF: 7.59
2016-01-01
Journal of Investigative Dermatology
Abstract:An immunosuppressant agent with negligible or acceptable toxicity may provide a better therapeutic strategy for treatment of allergic contact dermatitis. We identified a natural cyclopeptide, roseotoxin B, that effectively suppressed cell proliferation and the production of proinflammatory cytokines in activated T cells but exhibited little naive T-cell toxicity at concentrations of 0.3-1 mu mol/L. In addition, roseotoxin B inhibited the activation of AKT and signal transducer and activator of transcription-3, suppressed cell cycle-related signaling, caused G(0)/G(1) phase arrest, reduced ribosomal protein-S3 (RPS3)-dependent NF-kappa B-mediated IL-2 production, and increased autophagy in activated T cells. Furthermore, picryl chloride-induced allergic contact dermatitis was significantly ameliorated by roseotoxin B in mice. The effects of roseotoxin B were inhibited in LC3-knockout mice, indicating that roseotoxin B acts in an autophagy-dependent manner in T-cell-mediated skin diseases. Overall, this study showed a mechanism for roseotoxin B-induced autophagic cell death and provided a unique perspective on autophagy-mediated down-regulation of NF-kappa B signaling in activated T cells. The unique anti-inflammatory mechanism of roseotoxin B against activated T lymphocytes in allergic contact dermatitis suggests that it could be a potential target for the treatment of immune-related skin diseases.
What problem does this paper attempt to address?